{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T08:22:49Z","timestamp":1761294169183,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Living donor liver transplantation (LDLT) is an acceptable treatment option for hepatocellular carcinoma (HCC). Traditional transplant criteria aim at best utilization of donor organs with low risk of post transplant recurrence. In LDLT, long term recurrence free survival (RFS) of 50% is considered acceptable. The objective of the current study was to determine preoperative factors associated with high recurrence rates in LDLT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Between April 2012 and December 2019, 898 LDLTs were performed at our center. Out of these, 242 were confirmed to have HCC on explant histopathology. We looked at preoperative factors associated with \u2264\u00a050%RFS at 4\u2009years. For survival analysis, Kaplan Meier curves were used and Cox regression analysis was used to identify independent predictors of recurrence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Median AFP was 14.4(0.7\u201311,326.7) ng\/ml. Median tumor size was 2.8(range\u2009=\u20090.1\u201311) cm and tumor number was 2(range\u2009=\u20091\u201315). On multivariate analysis, AFP &gt;\u2009600\u2009ng\/ml [HR:6, CI: 1.9\u201318.4,<jats:italic>P<\/jats:italic>\u00a0=\u20090.002] and microvascular invasion (MVI) [HR:5.8, CI: 2.5\u201313.4,<jats:italic>P<\/jats:italic>\u00a0&lt;\u2009\u00a00.001] were independent predictors of 4\u2009year RFS\u2009\u2264\u200950%. When AFP was &gt;\u2009600\u2009ng\/ml, MVI was seen in 88.9% tumors with poor grade and 75% of tumors outside University of California San Francisco criteria. Estimated 4\u2009year RFS was 78% for the entire cohort. When AFP was &lt;\u2009600\u2009ng\/ml, 4\u2009year RFS for well-moderate and poor grade tumors was 88 and 73%. With AFP\u2009&gt;\u2009600\u2009ng\/ml, RFS was 53% and 0 with well-moderate and poor grade tumors respectively (<jats:italic>P<\/jats:italic>\u00a0&lt;\u2009\u00a00.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Patients with AFP\u2009&lt;\u2009600\u2009ng\/ml have acceptable outcomes after LDLT. In patients with AFP\u2009&gt;\u2009600\u2009ng\/ml, a preoperative biopsy to rule out poor differentiation should be considered for patient selection.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12885-020-07238-w","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T12:03:47Z","timestamp":1597233827000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["When to call it off: defining transplant candidacy limits in liver donor liver transplantation for hepatocellular carcinoma"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4875-603X","authenticated-orcid":false,"given":"Abu Bakar Hafeez","family":"Bhatti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ammal Imran","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rizmi","family":"Tahir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faisal Saud","family":"Dar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nusrat Yar","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haseeb Haider","family":"Zia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahzad","family":"Riyaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atif","family":"Rana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,12]]},"reference":[{"key":"7238_CR1","doi-asserted-by":"publisher","first-page":"S248","DOI":"10.1053\/j.gastro.2004.09.039","volume":"127","author":"TJ Song","year":"2004","unstructured":"Song TJ, Ip EW, Fong Y. Hepatocellular carcinoma: current surgical management. Gastroenterology. 2004;127:S248\u201360.","journal-title":"Gastroenterology."},{"key":"7238_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrgastro.2016.193","volume":"14","author":"G Sapisochin","year":"2017","unstructured":"Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14:203\u201317.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"7238_CR3","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJM199603143341104","volume":"334","author":"V Mazzaferro","year":"1996","unstructured":"Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693\u20139.","journal-title":"N Engl J Med"},{"key":"7238_CR4","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1053\/jhep.2001.24563","volume":"33","author":"FY Yao","year":"2001","unstructured":"Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394\u2013403.","journal-title":"Hepatology."},{"key":"7238_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/ajt.12907","volume":"15","author":"SG Lee","year":"2015","unstructured":"Lee SG. A complete treatment of adult living donor liver transplantation: a review of surgical technique and current challenges to expand indication of patients. Am J Transplant. 2015;15:17\u201338.","journal-title":"Am J Transplant"},{"key":"7238_CR6","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1097\/01.tp.0000446269.20934.d3","volume":"8","author":"KW Lee","year":"2014","unstructured":"Lee KW, Yi NJ, Suh KS. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience. Transplantation. 2014;8:S20\u20133.","journal-title":"Transplantation."},{"key":"7238_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/MOT.0000000000000294","volume":"21","author":"HW Lee","year":"2016","unstructured":"Lee HW, Suh KS. Expansion of the criteria for living donor liver transplantation for hepatocellular carcinoma. Curr Opin Organ Transplant. 2016;21:231\u20137.","journal-title":"Curr Opin Organ Transplant"},{"key":"7238_CR8","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/SLA.0b013e31820508f1","volume":"253","author":"D DuBay","year":"2011","unstructured":"DuBay D, Sandroussi C, Sandhu L, et al. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg. 2011;253:166\u201372.","journal-title":"Ann Surg"},{"key":"7238_CR9","doi-asserted-by":"publisher","first-page":"453","DOI":"10.21037\/hbsn.2016.08.07","volume":"5","author":"SK Hong","year":"2016","unstructured":"Hong SK, Lee KW, Kim HS, et al. Living donor liver transplantation for hepatocellular carcinoma in Seoul National University. Hepatobiliary Surg Nutr. 2016;5:453\u201360.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"7238_CR10","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s00268-017-4259-1","volume":"42","author":"FS Dar","year":"2018","unstructured":"Dar FS, Bhatti ABH, Qureshi AI, et al. Living Donor Liver Transplantation in South Asia: Single Center Experience on Intermediate-Term Outcomes. World J Surg. 2018;42:1111\u20139.","journal-title":"World J Surg"},{"key":"7238_CR11","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jceh.2019.04.052","volume":"9","author":"ABH Bhatti","year":"2019","unstructured":"Bhatti ABH, Dar FS, Qureshi AI, et al. Living donor liver transplantation for hepatocellular carcinoma: a single-center experience from Pakistan. J Clin Exp Hepatol. 2019;9:704\u20139.","journal-title":"J Clin Exp Hepatol"},{"key":"7238_CR12","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/hep.30413","volume":"69","author":"N Mehta","year":"2019","unstructured":"Mehta N, Dodge JL, Roberts JP, et al. Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng\/mL in Patients with Hepatocellular Carcinoma Leads to Improved Post transplant Outcomes. Hepatology. 2019;69:1193\u2013205.","journal-title":"Hepatology."},{"issue":"2","key":"7238_CR13","doi-asserted-by":"publisher","first-page":"72","DOI":"10.21037\/tgh.2017.09.05","volume":"16","author":"Q Lai","year":"2017","unstructured":"Lai Q, Iesari S, Melandro F, et al. The growing impact of alpha-fetoprotein in the field of liver transplantation for hepatocellular cancer: time for a revolution. Transl Gastroenterol Hepatol. 2017;16(2):72.","journal-title":"Transl Gastroenterol Hepatol"},{"key":"7238_CR14","doi-asserted-by":"publisher","first-page":"461","DOI":"10.21037\/hbsn.2016.11.05","volume":"5","author":"SH Kim","year":"2016","unstructured":"Kim SH, Moon DB, Kim WJ, et al. Preoperative prognostic values of \u03b1-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA-II) in patients with hepatocellular carcinoma for living donor liver transplantation. Hepatobiliary Surg Nutr. 2016;5:461\u20139.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"7238_CR15","doi-asserted-by":"publisher","first-page":"E491","DOI":"10.1111\/j.1399-0012.2011.01463.x","volume":"25","author":"K Shirabe","year":"2011","unstructured":"Shirabe K, Taketomi A, Morita K, et al. Comparative evaluation of expanded criteria for patients with hepatocellular carcinoma beyond the Milan criteria undergoing living-related donor liver transplantation. Clin Transpl. 2011;25:E491\u20138.","journal-title":"Clin Transpl"},{"key":"7238_CR16","doi-asserted-by":"crossref","unstructured":"Kim JM, Kwon CH, Joh JW, P et al. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma. Transplant Proc 2014; 46:726\u2013729.","DOI":"10.1016\/j.transproceed.2013.11.037"},{"key":"7238_CR17","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1097\/TP.0b013e31816b67e4","volume":"85","author":"SS Zheng","year":"2008","unstructured":"Zheng SS, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation. 2008;85:1726\u201332.","journal-title":"Transplantation."},{"key":"7238_CR18","doi-asserted-by":"crossref","unstructured":"Cuccurullo V, Di Stasio GD, Mazzarella G, et al. Microvascular Invasion in HCC: The Molecular Imaging Perspective. Contrast Media Mol Imaging. 2018;9487938.","DOI":"10.1155\/2018\/9487938"},{"key":"7238_CR19","doi-asserted-by":"publisher","first-page":"5308","DOI":"10.3748\/wjg.v20.i18.5308","volume":"20","author":"M Fujiki","year":"2014","unstructured":"Fujiki M, Aucejo F, Choi M, et al. Neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: where do we stand? World J Gastroenterol. 2014;20:5308\u201319.","journal-title":"World J Gastroenterol"},{"key":"7238_CR20","first-page":"292","volume":"61","author":"AR Haug","year":"2017","unstructured":"Haug AR. Imaging of primary liver tumors with positron emission tomography. Q J Nucl Med Mol Imaging. 2017;61:292\u2013300.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"7238_CR21","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00261-014-0256-0","volume":"40","author":"SY Ahn","year":"2015","unstructured":"Ahn SY, Lee JM, Joo I, et al. Prediction of microvascular invasion of hepatocellular carcinoma using gadoxetic acid enhanced MR and (18)F-FDG PET\/CT. Abdom Imaging. 2015;40:843\u201351.","journal-title":"Abdom Imaging"},{"issue":"7","key":"7238_CR22","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.dld.2018.03.014","volume":"50","author":"FP Russo","year":"2018","unstructured":"Russo FP, Imondi A, Lynch EN, Farinati F. When and how should we perform a biopsy for HCC in patients with liver cirrhosis in 2018? A review. Dig Liver Dis. 2018;50(7):640\u20136. https:\/\/doi.org\/10.1016\/j.dld.2018.03.014.","journal-title":"Dig Liver Dis"},{"issue":"5","key":"7238_CR23","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/dc.10097","volume":"26","author":"Z Guo","year":"2002","unstructured":"Guo Z, Kurtycz DF, Salem R, De Las Casas LE, Caya JG, Hoerl HD. Radiologically guided percutaneous fine-needle aspiration biopsy of the liver: retrospective study of 119 cases evaluating diagnostic effectiveness and clinical complications. Diagn Cytopathol. 2002;26(5):283\u20139. https:\/\/doi.org\/10.1002\/dc.10097.","journal-title":"Diagn Cytopathol"},{"issue":"5","key":"7238_CR24","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.ejso.2007.07.013","volume":"34","author":"P Wang","year":"2008","unstructured":"Wang P, Meng ZQ, Chen Z, et al. Diagnostic value and complications of fine needle aspiration for primary liver cancer and its influence on the treatment outcome-a study based on 3011 patients in China. Eur J Surg Oncol. 2008;34(5):541\u20136. https:\/\/doi.org\/10.1016\/j.ejso.2007.07.013.","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"7238_CR25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13000-020-00965-5","volume":"15","author":"L Zhang","year":"2020","unstructured":"Zhang L, Cai Z, Rodriguez J, Zhang S, Thomas J, Zhu H. Fine needle biopsy of malignant tumors of the liver: a retrospective study of 624 cases from a single institution experience. Diagn Pathol. 2020;15(1):43. Published 2020 May 6. https:\/\/doi.org\/10.1186\/s13000-020-00965-5.","journal-title":"Diagn Pathol"},{"key":"7238_CR26","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1053\/j.gastro.2012.05.052","volume":"143","author":"C Duvoux","year":"2012","unstructured":"Duvoux C, Roudot-Thoraval F, Decaens T, et al. Liver transplantation for hepatocellular carcinoma: a model including \u03b1-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012;143:986\u201394.","journal-title":"Gastroenterology."},{"key":"7238_CR27","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1053\/j.gastro.2017.09.025","volume":"154","author":"V Mazzaferro","year":"2018","unstructured":"Mazzaferro V, Sposito C, Zhou J, et al. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology. 2018;154:128\u201339.","journal-title":"Gastroenterology."},{"key":"7238_CR28","doi-asserted-by":"publisher","unstructured":"Grat M, Stypu\u0142kowski J, Morawski M, et al. Shadows Behind Using Simple Risk Models in Selection of Hepatocellular Carcinoma Patients for Liver Transplantation. Ann Surg. 2018. [Epub ahead of print. https:\/\/doi.org\/10.1097\/SLA.0000000000003176.","DOI":"10.1097\/SLA.0000000000003176"},{"key":"7238_CR29","doi-asserted-by":"publisher","unstructured":"ChangY, Cho Y, Lee JH, et al. Comparison of Models for Tumor Recurrence after Liver Transplantation for the Patients with Hepatocellular Carcinoma: A Multicenter Long-Term Follow-Up Study. Cancers 2019; 11, 9 . pii: E1295. doi: https:\/\/doi.org\/10.3390\/cancers11091295.1295.","DOI":"10.3390\/cancers11091295.1295"},{"key":"7238_CR30","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.surg.2013.04.056","volume":"154","author":"T Kaido","year":"2013","unstructured":"Kaido T, Ogawa K, Mori A, et al. Usefulness of the kyoto criteria the Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma. Surgery. 2013;154:1053\u201360.","journal-title":"Surgery"},{"key":"7238_CR31","doi-asserted-by":"publisher","first-page":"411","DOI":"10.5500\/wjt.v6.i2.411","volume":"24","author":"SD Lee","year":"2016","unstructured":"Lee SD, Lee B, Kim SH, et al. Proposal of new expanded selection criteria using total tumor size and (18)F-flourodeoxyglucose-positron emission tomography\/computed tomography for living donor liver transplantation in patients with hepatocellular carcinoma: The National Cancer Center Korea criteria. World J Transplant. 2016;24:411\u201322.","journal-title":"World J Transplant"},{"key":"7238_CR32","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1097\/SLA.0000000000001578","volume":"263","author":"JH Lee","year":"2016","unstructured":"Lee JH, Cho Y, Kim HY, et al. Serum tumor markers provide refined prognostication in selecting liver transplantation candidate for hepatocellular carcinoma patients beyond the Milan criteria. Ann Surg. 2016;263:842\u201350.","journal-title":"Ann Surg"},{"key":"7238_CR33","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.jhep.2016.10.038","volume":"66","author":"A Notarpaolo","year":"2017","unstructured":"Notarpaolo A, Layese R, Magistri P, et al. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. J Hepatol. 2017;66:552\u20139.","journal-title":"J Hepatol"},{"key":"7238_CR34","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1097\/TP.0000000000002094","volume":"102","author":"JM Giard","year":"2018","unstructured":"Giard JM, Mehta N, Dodge JL, Roberts JP, Yao FY. Alpha-Fetoprotein Slope >7.5 ng\/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma. Transplantation. 2018;102:816\u201322.","journal-title":"Transplantation."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07238-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07238-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07238-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T17:13:34Z","timestamp":1696526014000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07238-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,12]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7238"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07238-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"type":"electronic","value":"1471-2407"}],"subject":[],"published":{"date-parts":[[2020,8,12]]},"assertion":[{"value":"30 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The institutional review board and ethics committee of Shifa International Hospital\/Shifa Tameer-e-Millat university approved the study (IRB # 013\u2013833-2020). A written consent to participate was taken from patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"754"}}